News
The day at a glance · 4 min read
Mood · Steady
+15
Sentiment, −100 to +100
CRO Market Value (2025)
$45.33B
CRO Market Forecast (2033)
$83.31B
Registered Clinical Studies
569,000+
Key driverDiagnostics market evolution toward point-of-care testing and CRO market growth driving sector attention amid biotech deal activity
Daily briefHealthcare· Money365.Market AI ·

Healthcare Diagnostics, CRO Markets, Oncology Deals Lead Sector

PCR and immunoassay markets shift to point-of-care; pharmaceutical CRO sector valued at $45.33B; biotech partnerships expand

Diagnostics Market Transformation

Neutral
ABTTMO
Abbott Laboratories (ABT), Roche, and Siemens Healthineers are among 64 players analyzed in a new immunoassay market report showing point-of-care testing, falling prices, and PCR technology threatening traditional lab models. Hospital and outpatient lab spending is shifting as forecasts by application, technology, and care setting reveal changing diagnostic industry dynamics.
Thermo Fisher Scientific (TMO) and Roche are profiled among 89 companies in a separate PCR market report forecasting growth for qPCR, digital PCR, and multiplex testing. The pandemic accelerated polymerase chain reaction technology adoption, with syndromic multiplex panels reshaping molecular diagnostics from clinical labs to point-of-care settings over a five-year forecast period.
Avricore Health's wholly owned subsidiary HealthTab completed an integration with HeartEye, a UK provider of AI-based retinal cardiovascular risk assessment, creating a new referral pathway into community pharmacy. People found at elevated cardiovascular risk by a HeartEye retinal scan at their optician can be referred into community pharmacy settings.
Citi reiterated Abbott Laboratories (ABT) and Dexcom as its top picks in the medtech sector, highlighting them as standout opportunities while pointing to diverging fortunes across the industry.

Pharmaceutical CRO Market Expansion

Bullish
TMO
The global pharmaceutical CRO market was valued at an estimated $45.33B in 2025 and is forecast to reach $83.31B by 2033, according to a report profiling IQVIA, ICON, Thermo Fisher Scientific (TMO), Medpace, and five other key players. The 230-page analysis shows how more than 569,000 registered clinical studies, CRO consolidation, and AI-driven trial models are reshaping outsourcing strategy for pharma and biotech leaders. Five-year forecasts break down growth by type, molecule type, services, therapeutic area, and region as the contract research organization sector expands.

Biotech Partnerships & Oncology Deals

Bullish

InnoCare YTD Return

8.08%+8.08%

InnoCare 3-Year TSR

119.32%+119.32%

Halozyme-Argenx Targets

8
LLYREGN
InnoCare Pharma (SEHK:9969) announced a research collaboration and license agreement with Eli Lilly (LLY) to pursue up to five drug targets addressing critical unmet medical needs. The partnership drew fresh attention after InnoCare Pharma's shares posted a year-to-date return of 8.08% and three-year total shareholder return of 119.32%, despite recent weakness with seven-day return down 8.65% and 30-day return down 8.72%.
Biohaven (BHVN) announced in September a clinical supply agreement with Regeneron Pharmaceuticals (REGN) to test BHV-1530 in combination with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical data suggesting potential synergy with Anti-PD-1 therapy. This new BHV-1530 collaboration builds on an existing supply agreement for Biohaven's next-generation TROP2-directed ADC BHV-1510, deepening Regeneron's involvement across Biohaven's oncology pipeline.
Halozyme Therapeutics (HALO) extended its ENHANZE collaboration with argenx to cover two more exclusive targets, taking the total to eight and adding fresh attention to the stock's partnership-driven revenue model. Under the expanded agreement, Halozyme is eligible for milestone payments linked to development and commercial progress, as well as royalties on net sales of ENHANZE-based products.

Medical Devices & Surgical Robotics

Bullish
ISRG
Intuitive Surgical (ISRG) received bullish coverage initiation from Barclays in early October, describing it as a high-quality healthcare equipment company amid a softer medical devices backdrop. Market debate sharpened around Intuitive Surgical's valuation and competitive position, with commentary highlighting both its strong balance sheet and rising competitive pressures. The company's earnings release expected on October 20 is anticipated to show year-over-year growth in earnings per share and revenue.

Big Pharma & Biotech

Neutral

Axsome Revenue Growth

65%+65%
MRKMRNALLYJNJ
Bayer and Merck (MRK)'s ADEMPAS (Riociguat) is identified as the leading therapy for chronic thromboembolic pulmonary hypertension, according to a 135-page market report tracking the seven major markets through extended forecast periods. The report notes a limited pipeline leaves the market without a curative leader, as combination regimens and balloon pulmonary angioplasty reshape CTEPH treatment approaches.
Moderna (MRNA) was compared to Axsome Therapeutics in an analysis noting Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.
Jim Cramer discussed Amgen (AMGN) while reviewing the Dow Jones Industrial Average's third-quarter performance and shifted attention to Johnson & Johnson (JNJ). When asked whether Novo Nordisk (NVO) or Eli Lilly (LLY) offered better upside over three to five years, Cramer replied he would still go with Lilly, calling it a high-quality stock.

Healthcare Valuation & Strategy

Neutral
UNH
UnitedHealth Group (UNH) represents a different valuation story than it was a few years ago, as the stock used to command the kind of premium multiple investors were willing to pay for a high-quality healthcare compounder. That premium has largely disappeared after a difficult stretch of higher medical costs and pressure across parts of the business, prompting analysis of whether the stock is finally undervalued following the price-to-earnings ratio reset.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy